Clinical trialPhase 1
VERVE-102 Heart-2
NCT06164730
Open-label Phase 1, interim n=35, шесть single-dose cohorts 0.3–1.0 mg/kg; in vivo adenine base editing PCSK9.
No news refers to this card yet.
Scales
Identifiers
- NCT
- NCT06164730
Original sources
Details
- Phase
- Phase 1
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.